Teva’s Austedo Fails a Pair of Tourette Syndrome TrialsBusiness, Clinical Trials, Financials, Motor Movement, Neurodevelopmental Disorders, Pediatric, R&D, Tics, Tourette Syndrome, VMAT2 InhibitorsTeva Pharmaceutical’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials. Read more February 20, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/02/Teva-Tourette-RD-BioSpace-2-20-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-02-20 12:06:452020-02-21 13:14:38Teva’s Austedo Fails a Pair of Tourette Syndrome Trials